Nesfrotamig
Based on 1 Customer Validation
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.22%
- CAS No.: 2966936-23-0
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
IgG1-kappa-[scFv]2-lambda-heavy
Human
ERBB2 & TNFRSF9
Nesfrotamig binds to 4-1BB-expressing Jurkat cells and HER2-expressing HCC1954 cells in a dose-dependent manner[1].
Nesfrotamig induces 4-1BB activation in a HER2 expression-dependent manner across multiple human cancer cell lines, with higher induction fold observed in cell lines with higher normalized HER2 expression levels[1].
Nesfrotamig (0.01 μg/mL-10 μg/mL) inhibits the proliferation of BT-474 cells in a dose-dependent manner, and its potency is comparable to that of Trastuzumab (HY-P9907)[1].
ABL105 potently activates the 4-1BB signaling pathway in three HER2-expressing tumor cell lines, NCI-N87, JIMT-1 and HCC1954[2].
ABL105 induces IFN-γ secretion and subsequent tumor cell lysis in a co-culture system of hPBMC and HER2-expressing tumor cells[2].
YH32367 induces IFN-γ secretion and subsequent tumor cell death in a co-culture system of hPBMC and HER2-expressing tumor cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Nesfrotamig (ABL105) (10 mg/kg; i.p.; twice weekly; 4 weeks) induces complete tumor regression in h4-1BB KI mice bearing hHER2/MC38 colorectal tumors and establishes durable, tumor-specific memory T cell immunity that prevents tumor re-challenge[1].
Nesfrotamig exhibits superior tumor-eradicating efficacy and induces long-term anti-tumor immunity in MC38/hHER2-bearing h4-1BB KI mice compared to benchmark HER2-targeted and 4-1BB/HER2-bispecific agents[3].
Nesfrotamig demonstrates greater monotherapy efficacy than a benchmark 4-1BB/HER2-bispecific agent in HER2-low tumor-bearing h4-1BB KI mice, and exhibits synergistic anti-tumor activity when combined with anti-PD-1 antibody[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:humanized PBMC-engrafted mice with Breast cancer[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; twice weekly; 4 weeks
-
Result:Reduced mean tumor volume to ~50 mm3 by 29 days post-tumor inoculation.
Increased tumor infiltration of CD4+, CD8+, CD4+ effector memory, and CD8+ effector memory T cells significantly relative to control groups.
Showed lower fold induction of hCD45-positive cells in peripheral blood than anti-4-1BB antibody control.
Maintained F4/80+ cell counts in the liver comparable to control groups.
-
Animal Model:human 4-1BB knock-in (h4-1BB KI) mice with Colorectal cancer[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; 4 weeks
-
Result:Reduced mean tumor volume to near 0 mm3 by 40 days post-tumor inoculation and maintained suppression through 90 days.
Enabled complete protection against re-challenge with hHER2/MC38 cells in mice cured of initial tumors, while B16F10 tumors grew normally.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa-[scFv]2-lambda-heavy
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2966936-23-0
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
YH32367; ABL105
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nesfrotamig Related Classifications
HY-P991149 Related Classifications
Powered by Bioz